Do you like growth stocks? Well, if you do and you are on the lookout for some new investments when the market reopens then read on.
Listed below are a couple of top ASX growth stocks that analysts have recently named as buys. Let's see what they are saying about these growing companies this month:
The first ASX growth stock that could be a buy according to analysts is Breville.
It designs, develops, markets, and distributes small electrical kitchen appliances in the consumer products industry. As well as the eponymous Breville brand, the company's portfolio includes the Kambrook, Baratza, Sagem and Lelit brands.
Analysts at Ord Minnett are positive on the company. Particularly given how they believe that the company is on the brink of a return to form with accelerating sales growth. This is expected to be driven by new products and acquisitions. The broker recently said:
Breville has experienced a notable decline in its return on capital over the past five years, but Ord Minnett views FY24 as the cyclic allow for returns. Our projections indicate a rebound as sales growth accelerates and operational leverage improves. This sales growth is expected to stem from improved sales momentum, innovative product development, and recent strategic acquisitions.
Ord Minnett currently has an accumulate rating and $38.00 price target on the company's shares.
Another ASX growth stock that could be a buy right now according to analysts is Readytech.
It is a leading software as a service (SaaS) provider of mission critical software to the tertiary education, government, justice, and enterprise markets.
The team at Morgans is bullish on the company. With its shares trading at a deep discount to historic averages despite having strong growth prospects, its analysts believe that the software company is a great example of growth on offer at a reasonable price. They recently said:
Its products include student management, payroll and HR solutions, and enterprise resource planning (ERP) to local government and legal case management. RDY's recent organic growth trajectory demonstrates its ability to deliver our forecast 14.5% CAGR EBITDA growth over coming years. Despite this, the company is trading at a ~20% discount to its historic average EBITDA multiple of ~11x, which we believe represents compelling value.
Morgans currently has an add rating and $3.74 price target on its shares.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。